Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis

Annals of the Rheumatic Diseases

Volumn 63, Issue 4, 2004, Pages 348-353

  Metselaar, J M ^a,d   Van Den Berg, W B ^b   Holthuysen, A E M ^b   Wauben, M H M ^c   Storm, G ^a,d   Van Lent, P L E M ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNYPHAR ^*

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; COLLAGEN TYPE 2; COLLOIDAL GOLD; DIPALMITOYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLCHOLINE; GLUCOCORTICOID; LIPOSOME; MACROGOL; MACROGOL 2000; PREDNISOLONE 21 PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BLOOD VESSEL; CARTILAGE DEGENERATION; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; DRUG UPTAKE; KNEE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEROID THERAPY; SYNOVIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; GLUCOCORTICOIDS; HINDLIMB; INJECTIONS, INTRAVENOUS; JOINTS; LIPOSOMES; MALE; MICE; MICE, INBRED DBA; PREDNISOLONE; SPLEEN; SYNOVIAL MEMBRANE;

EID: 1842505688     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.009944     Document Type: Article

References (37)

1. Harris ED. Rheumatoid arthritis: pothophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
2. Bodman KB, Roitt IM. The pothophysiology of rheumatoid arthritis. Fund Am Clin Immunl 1994;2:73-81.
3. Van den Berg WB, Van Lent PLEM. The role of macrophages in chronic arthritis. Immunobiology 1996;195:614-23.
4. Van Lent PLEM, Holthuysen AEM, Van den Bersselaar L, Van Rooijen N, Van de Putte LBA, Van den Berg WB. Role of macrophage-like synovial lining cells in localization and expression of experimental arthritis. Scand J Rheumatol 1995;24(suppl 101):83-9.
5. Cutolo M, Sulli A, Barone A, Seriolo B, Accardo S. Macrophages, synovial tissue and rheumatoid arthritis. Clinical Exp Rheumatol 1993;11:331-9.
6. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR. Macrophages in rheumatoid arthritis. Arthritis Res 2000;2:189-202.
7. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994;174:83-93.
8. Oussoren C, Storm G. Liposomes ta target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 200;50:143-56.
9. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of porticulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release 2002;79:29-40.
10. Van Lent PL, Holthuysen AE, Van Rooijen N, Van De Putte LB, Van Den Berg WB. Local removal of phagocytic synovial lining cells by clodronate-liposomes decreases cartilage destruction during collagen type II arthritis. Ann Rheum Dis 1998;57:408-13.
11. Barrera P, Blom A, van Lent PL, van Bloois L, Beijnen JH, van Rooijen N, et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum 2000;43:1951-9.
12. Camilleri JP, Williams AS, Amos N, Douglas-Jones AG, Williams BD. Liposomal clodronate depletes synovial macrophages, suppresses inflammation and prevents radiological progression in adjuvant arthritis. Arthritis Rheum 1995;38(suppl 9):1319.
13. Richards PJ, Williams AS, Goodfellow RM, Williams BD. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology (Oxford) 1999;38:818-25.
14. Richards PJ, Williams BD, Williams AS. Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate. Rheumatology (Oxford) 2001;40:978-87.
15. Camilleri JP, Williams AS, Amos N, Douglas-Jones AG, Love WG, Williams BD. The effect of free and liposome-encapsulated clodronate on the hepatic mononuclear phagocyte system in the rat. Clin Exp Immunol 1995;99:269-75.
16. Joyce DA, Gimblett G, Steer JH. Targets of glucocorticoid action on TNF-alpha release by macrophages. Inflamm Res 2001;50:337-40.
17. Amano Y, Lee SW, Allison AC. Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin-1 beta, and interleukin-6: mediation by decreased mRNA stability. Mol Pharmacol 1993;43:176-82.
18. Wong PK, Cuello C, Bertouch JV, Roberts-Thomson PJ, Ahern MJ, Smith MD, et al. Effects of pulse methylprednisolone on macrophage chemotactic protein-1 and macrophage inflammatory protein-1alpha in rheumatoid synovium. J Rheumatol 2001;28:2634-6.
19. Cutolo M, Foppiani L, Prete C, Ballarino P, Sulli A, Villaggio B, et al. Hypothalamic-pituitary-adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids. J Rheumatol 1999;26:247-50.
20. ACR. Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996;39:713-22.
21. Saag KG. Glucocorticoid use in rheumatoid arthritis. Curr Rheumatol Rep 2002;4:218-25.
22. Snell ES. The pharmacological properties of corticosteroids in relation to clinical efficacy. Br J Dermatol 1976;94(suppl 12):15-23.
23. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992;1113:171-99.
24. Oku N, Namba Y. Long-circulating liposomes. Crit Rev Ther Drug Carrier Syst 1994;11:231-70.
25. Woodle MC, Newman MS, Cohen JA. Sterically stabilized liposomes: physical and biological properties. J Drug Target 1994;2:397-403.
26. Laverman P, Boerman OC, Oyen WJ, Dams ET, Storm G, Corstens FH. Liposomes for scintigraphic detection of infection and inflammation. Adv Drug Deliv Rev 1999;37:225-35.
27. Metselaar JM, Wauben MH, Wagenaar-Hilbers JP, Boerman OC, Storm G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum 2003;48:2059-66.
28. Amselem S, Gabizon A, Barenholz Y. A large-scale method for the preparation of sterile and non-pyrogenic liposomal formulations of defined size distributions for clinical use. In: Gregoriodis G, ed. Liposome technology. Boca Raton, FL: CRC Press, 1993:501-25.
29. Rouser G, Fkeischer S, Yamamoto A. Two-dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970;5:494-6.
30. Huang SK, Hong K, Lee KD, Papahadjopoulos D, Friend DS. Light microscopic localization of silver-enhanced liposome-entrapped colloidal gold in mouse tissues. Biochim Biophys Acta 1991;1069:117-21.
31. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980;283:666-8.
32. Weusten BLAM, Jacobs JWG, Bijlsma JWJ. Corticosteroid pulse therapy in active rheumatoid arthritis. Semin Arthritis Rheum 1993;23:183-92.
33. Roujeau JC. Pulse glucocorticoid therapy. The 'big shot' revisited. Arch Dermatol 1996;132:1499-502.
34. Liebling MR, Leib E, McLaughlin K, Blocka K, Furst DE, Nyman K, et al. Pulse methylprednisolone in rheumatoid arthritis: a double-blind cross-over trial. Ann Intern Med 1981;94:21-6.
35. Hansen TM, Dickmeiss E, Jans H, Ingemann Hansen T, Ingeman-Nielsen M, Lorenzen I. Combination of methylprednisolone pulse therapy and remission inducing drugs in rheumatoid arthritis. Ann Rheum Dis 1987;46:290-5.
36. Schiffelers RM, Storm G, Bakker-Woudenberg IA. Host factars influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. Pharm Res 2001;18:780-7.
37. Laverman P, Dams ET, Storm G, Hafmans TG, Croes HJ, Oyen WJ, et al. Microscopic localization of PEG-liposomes in a rat model of focal infection. J Control Release 2001;75:347-55.